The overall objectives of is to Improve the quality and quantity of cancer research at the University of Oklahoma Hearth Sciences Center (OUHSC), to increase NIH funding in Oklahoma through the mentoring of promising junior investigators (PJIs) and to develop support for the infrastructure for cancer research, this COBRE grant will greatly strengthen cancer research in Oklahoma and enhance the research base, infrastructure, and core capacities of the Cancer Center. The focused and structured mentoring experience that the COBRE grant supports will be a determinative influence helping PJIs achieve independent national funding. Finally, as has been seen on campus in the areas of Vision, Diabetes, Dental Sciences and Microbial Pathogenesis, the CoBRE grant will help accelerate the development of the Cancer Center as it progresses towards a submitting a competitive NCI Cancer Center Support Grant application.
The Specific Aims of this CBRE application are: 1. To mentor promising junior investigators (PJIs) In cancer research, enabling them to become independent NIH-funded investigators. Four PJIs have been selected. Each has been assigned a mentor and a co-mentor who are established cancer researchers in Oklahoma with expertise related to the PJI's project. The four PJIs have diverse but related projects that are integrated under the overall theme of """"""""Tumor Biology: Resistance to Cancer Therapy and Mitigating Strategies."""""""" 2. To establish and develop research infrastructure to support cancer research, optimize the research environment for the PJIs, and form a core resource for the developing Stephenson Oklahoma Cancer Center. Four shared Cores will be established in this COBRE to assist the PJI projects and to serve the cancer research community in Oklahoma. 3. To foster and enhance collaborations between basic scientists and clinicians, and to facilitate translational research directed toward the development of new diagnostics and treatments for cancer.
Cancer represents a major health burden in the US. Ultimately, alleviating the burden of cancer will come from research: the generation of new ideas and, consequently, the development of novel agents. A COBRE grant will allow the Oklahoma Cancer Center to provide PJIs a focused mentoring experience to help them mature into independently-funded investigators contributing to the overall fight against cancer.
|Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113|
|Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143|
|Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934|
|Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49|
|Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74|
|Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042|
|Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249|
|Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384|
|Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515|
|Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:|
Showing the most recent 10 out of 68 publications